


Supplementary Materials

Supplementary Figure S1. Flowchart of the patient selection process



Supplementary Table S1. Changes in LLT due to safety reasons (N=57)

Prior LLT	Current LLT				Overall
	Rosuvastatin	Rosuvastatin + ezetimibe	Atorvastatin	Atorvastatin + ezetimibe	
Rosuvastatin	0 (0.0)	3 (5.3)	0 (0.0)	2 (3.5)	5 (8.8)
Rosuvastatin + ezetimibe	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.8)
Atorvastatin	9 (15.8)	30 (52.6)	1 (1.8)	3 (5.3)	43 (75.4)
Atorvastatin + ezetimibe	0 (0.0)	5 (8.8)	2 (3.5)	1 (1.8)	8 (14.0)
Overall	10 (17.7)	38 (66.7)	3 (5.3)	6 (10.5)	57 (100.0)

LLT, lipid-lowering therapy.

Supplementary Table S2. Clinical characteristics associated with the type of statin therapy (N=1,570)

Variable	Statin therapy		p-value ¹
	Rosuvastatin N (%)	Atorvastatin N (%)	
Cardiovascular disease			
Yes	600 (49.3)	616 (50.7)	<0.001
No	219 (61.9)	135 (38.1)	
Arterial hypertension			
Yes	604 (52.6)	544 (47.4)	0.569
No	215 (50.9)	207 (49.1)	
Familial hypercholesterolemia			
Yes	88 (72.7)	33 (27.3)	<0.001
No	731 (50.4)	718 (49.6)	
Chronic kidney disease			
Yes	61 (46.2)	71 (53.8)	0.172
No	758 (52.7)	680 (47.3)	
Microalbuminuria			
Yes	95 (58.3)	68 (41.7)	0.115
No	724 (51.5)	683 (48.5)	
Diabetes mellitus			
Yes	268 (49.2)	277 (50.8)	0.090
No	551 (53.8)	474 (46.2)	
Retinopathy			
Yes	48 (60.8)	31 (39.2)	0.133
No	771 (51.7)	720 (48.3)	
Neuropathy			
Yes	23 (51.1)	22 (48.9)	>0.999
No	796 (52.2)	729 (47.8)	

¹Chi-square